Top

Published in:

01-08-2011 | PRECLINICAL STUDIES

Anoikis induction and metastasis suppression by a new integrin αvβ3 inhibitor in human melanoma cell line M21

Authors: Yongci Zhang, Ming Yang, Qing Ji, Dongmei Fan, Hui Peng, Chunzheng Yang, Dongsheng Xiong, Yuan Zhou

Published in: Investigational New Drugs | Issue 4/2011

Summary

Integrin αvβ3 plays a critical role in the survival and metastasis process of cancer cells. It is therefore desirable to develop new types of small molecule inhibitors of integrin αvβ3. IH1062 (3, 5-dichloro-phenylbiguanide) is a novel small molecule inhibitor of integrin αvβ3 that we have recently discovered. In this study, we investigated the induction effects of anoikis in human melanoma cell line M21 by IH1062, by detecting caspase activity, measuring the expression levels of apoptosis-related proteins, and performing the AnnexinV/PI apoptosis assay. Furthermore, we established a melanoma pulmonary metastasis mouse model in order to evaluate the suppression of metastasis by IH1062 in vivo. Our results demonstrate that IH1062 triggered human melanoma M21 cells to undergo anoikis by interrupting the attachment of M21 cells to extracellular matrix, reducing the phosphorylation of focal adhesion kinase, decreasing survivin and the ratio of Bcl-2/Bax proteins, and activating caspase cascades in vitro. Additionally, IH1062 showed markedly anti-metastatic effects in the pulmonary metastasis model in vivo, which makes it a promising lead to develop new drugs for anti-metastasis therapies.

Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569–571. doi:10.1126/science.7512751 PubMedCrossRef

Jones JI, Prevette T, Gockerman A et al (1996) Ligand occupancy of the alpha-V-beta3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Proc Natl Acad Sci U S A 93:2482–2487. doi:10.1073/pnas.93.6.2482 PubMedCrossRef

Petitclerc E, Strömblad S, von Schalscha TL et al (1999) Integrin αvβ3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res 59:2724–2730PubMed

Reinmuth N, Liu W, Ahmad SA et al (2003) αvβ3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res 63:2079–2087PubMed

Lössner D, Abou-Ajram C, Benge A et al (2008) Integrin alphavbeta3 mediates upregulation of epidermal growth-factor receptor expression and activity in human ovarian cancer cells. Int J Biochem Cell Biol 40:2746–2761. doi:10.1016/j.biocel.2008.05.014 PubMedCrossRef

Zhou Y, Peng H, Ji Q et al (2006) Discovery of small molecule inhibitors of integrin alphavbeta3 through structure-based virtual screening. Bioorg Med Chem Lett 16:5878–5882. doi:10.1016/j.bmcl.2006.08.061 PubMedCrossRef

Maubant S, Dizier DS, Boutillon M et al (2006) Blockade of αvβ3 and αvβ5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood 108:3035–3044. doi:10.1182/blood-2006-05-023580 PubMedCrossRef

Giancotti FG, Ruoslahti E (1999) Integrin signaling. Science 285:1028–1032. doi:10.1126/science.285.5430.1028 PubMedCrossRef

Patsenker E, PopovY WM et al (2007) Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. J Hepatol 46:878–887. doi:10.1016/j.jhep.2006.11.011 PubMedCrossRef

10.

Chatterjee S, Brite KH, Matsumura A (2001) Induction of apoptosis of integrin-expressing human prostate cancer cells by cyclic Arg-Gly-Asp peptides. Clin Cancer Res 7:3006–3011PubMed

11.

Gong W, Liu Y, Huang B et al (2008) Recombinant CBD–HepII polypeptide of fibronectin inhibits αvβ3 signaling and hematogenous metastasis of tumor. Biochem Biophys Res Commun 367:144–149. doi:10.1016/j.bbrc.2007.12.110 PubMedCrossRef

12.

Zhou XY, Murphy FR, Gehdu N et al (2004) Engagement ofαvβ3 integrin regulates proliferation and apoptosis of hepatic stellate cells. J Biol Chem 279:23996–4006. doi:10.1074/jbc.M311668200 PubMedCrossRef

13.

Shin S, Sung BJ, Cho YS et al (2001) An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40:1117–1123. doi:10.1021/bi001603q PubMedCrossRef

14.

von Wnuck LK, Keul P, Ferri N et al (2006) Integrin-mediated transcriptional activation of inhibitor of apoptosis proteins protects smooth muscle cells against apoptosis induced by degraded collagen. Circ Res 98:1490–1497. doi:10.1161/01.RES.0000229267.77982.0d CrossRef

15.

Cao Q, Cai W, Niu G et al (2008) Multimodality Imaging of IL-18-binding protein-Fc therapy of experimental lung metastasis. Clinical cancer research 14:6137–6145. doi:10.1158/1078-0432.CCR-08-0049 PubMedCrossRef

16.

Chen Q, Manning CD, Millar H et al (2008) CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells. Clin Exp Metastasis 25:139–148. doi:10.1007/s10585-007-9132-4 PubMedCrossRef

17.

Zhao Y, Bachelier R, Treilleux I et al (2007) Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 67:5821–5830. doi:10.1158/0008-5472.CAN-06-4499 PubMedCrossRef

Title: Anoikis induction and metastasis suppression by a new integrin αvβ3 inhibitor in human melanoma cell line M21
Authors: Yongci Zhang
Ming Yang
Qing Ji
Dongmei Fan
Hui Peng
Chunzheng Yang
Dongsheng Xiong
Yuan Zhou
Publication date: 01-08-2011
Publisher: Springer US
Published in: Investigational New Drugs / Issue 4/2011
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-010-9616-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 4/2011

Anticancer activity and mode of action of titanocene C

Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study

Cribrostatin 6 induces death in cancer cells through a reactive oxygen species (ROS)-mediated mechanism

Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo

Proposal for size justification of expanded cohort at phase-2-recommended dose

The anti-proliferative side effects of AEE788, a tyrosine kinase inhibitor blocking both EGF- and VEGF-receptor, are liver-size-dependent after partial hepatectomy in rats

Keynote webinar | Spotlight on antibody–drug conjugates in cancer